Adar1 Capital Management, LLC Viridian Therapeutics, Inc.\De Transaction History
Adar1 Capital Management, LLC
- $530 Billion
- Q2 2024
A detailed history of Adar1 Capital Management, LLC transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Adar1 Capital Management, LLC holds 8,000 shares of VRDN stock, worth $177,360. This represents 0.02% of its overall portfolio holdings.
Number of Shares
8,000
Previous 2,550
213.73%
Holding current value
$177,360
Previous $44.7 Million
133.1%
% of portfolio
0.02%
Previous 0.01%
Shares
2 transactions
Others Institutions Holding VRDN
# of Institutions
151Shares Held
61.9MCall Options Held
133KPut Options Held
207K-
Black Rock Inc. New York, NY4.77MShares$106 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.92MShares$87 Million1.68% of portfolio
-
Vr Adviser, LLC New York, NY3.88MShares$86.1 Million5.54% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.35MShares$74.2 Million0.0% of portfolio
-
Lee Ainslie Maverick Capital LTD | Dallas, Tx3.31MShares$73.3 Million0.85% of portfolio
About Viridian Therapeutics, Inc.\DE
- Ticker VRDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,888,900
- Market Cap $884M
- Description
- Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...